Literature DB >> 19960410

Antiallergic herbal composition from Scutellaria baicalensis and Phyllostachys edulis.

Dong-Seon Kim1, Eun-Jung Son, Miran Kim, Young-Moon Heo, Jeong-Bum Nam, Jai Youl Ro, Sung-Sick Woo.   

Abstract

We aimed to find antiallergic agents from natural sources using mast cells activated during allergic reaction. We screened over 2000 plants for blockade of histamine release and identified two of them, S. baicalenesis and P. edulis. Bioassay-guided fractionation led to two main constituent flavonoids, baicalin from S. baicalenesis roots and isoorientin from P. edulis leaves. Based on these two compounds, two standardized extracts (SSBE and SPEE) and a combined standardized herb composition (SHC) were developed. SSBE, SPEE, and SHC remarkably inhibited histamine and leukotriene release from mast cells activated by anti-OVA/OVA binding, and SHC showed a stronger inhibition than either extract alone. SHC also showed greater inhibition potency than either aspirin or cromolyn, which are known antiallergic agents. Our results suggest that SHC reduce degranulation during mast cell activation and could be a promising candidate for the treatment of immune/allergic diseases related to mast cells. Georg Thieme Verlag KG Stuttgart. New York.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960410     DOI: 10.1055/s-0029-1240649

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  3 in total

1.  Phyllostachys edulis compounds inhibit palmitic acid-induced monocyte chemoattractant protein 1 (MCP-1) production.

Authors:  Jason K Higa; Zhibin Liang; Philip G Williams; Jun Panee
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 2.  A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis.

Authors:  Zi-Long Wang; Shuang Wang; Yi Kuang; Zhi-Min Hu; Xue Qiao; Min Ye
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

3.  Therapeutic effect of Jinzhen oral liquid for hand foot and mouth disease: a randomized, multi-center, double-blind, placebo-controlled trial.

Authors:  Jun Liu; Guo-Liang Zhang; Gui-Qin Huang; Li Li; Chun-Ping Li; Mei Wang; Xiao-Yan Liang; Di Xie; Chang-Ming Yang; Yan Li; Xiu-Rong Sun; Hong-Sen Zhang; Bai-Song Wan; Wei-Hua Zhang; Hao Yu; Ru-Yang Zhang; Ya-Nan Yu; Zhong Wang; Yong-Yan Wang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.